{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:36:45Z","timestamp":1784547405963,"version":"3.55.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T00:00:00Z","timestamp":1687478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms are rare in childhood. They are categorized as Philadelphia chromosome-positive and Philadelphia chromosome-negative. Chronic myeloid leukemia (CML) is the most common myeloproliferative disease in which the Philadelphia chromosome is detected as a result of BCR-ABL rearrangements. In others, the most common genetic abnormality is JAK2V617F mutation. The coexistence of these 2 abnormalities in CML is unexpected, and rare cases have recently been reported in adults. We present a child who had a very high platelet count in which we found this coexistence. The clinical presentation, laboratory findings, management, and prognosis of this coexistence is challenging in such a rare condition.<\/jats:p>","DOI":"10.1093\/labmed\/lmad053","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T22:50:43Z","timestamp":1687647043000},"page":"e170-e176","source":"Crossref","is-referenced-by-count":1,"title":["Is very high platelet count always associated with essential thrombocythemia? An unusual presentation in a child"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6219","authenticated-orcid":false,"given":"Elif Habibe","family":"Aktekin","sequence":"first","affiliation":[{"name":"Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University , Adana , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-8229","authenticated-orcid":false,"given":"Nalan","family":"Yazici","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University , Adana , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-3822","authenticated-orcid":false,"given":"\u0130lknur","family":"Kozano\u011flu","sequence":"additional","affiliation":[{"name":"Department of Physiology and the Apheresis Unit Adult Bone Marrow Transplant Centre, Baskent University , Adana , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5268-1210","authenticated-orcid":false,"given":"Ay\u015fe","family":"Erbay","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Division of Pediatric Hematology-Oncology, Baskent University , Adana , Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,23]]},"reference":[{"key":"2023110721223212100_CIT0001","author":"Howlader","year":"2020"},{"issue":"4","key":"2023110721223212100_CIT0002","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11912-021-01025-x","article-title":"Chronic myelogenous leukemia in childhood","volume":"23","author":"Smith","year":"2021","journal-title":"Curr Oncol Rep."},{"issue":"1","key":"2023110721223212100_CIT0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1093526617698601","article-title":"A rare case of pediatric chronic myelogenous leukemia presenting with severe thrombocytosis without leukocytosis","volume":"21","author":"Huho","year":"2018","journal-title":"Pediatr Dev Pathol."},{"issue":"6","key":"2023110721223212100_CIT0004","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/MPH.0000000000001154","article-title":"Pediatric chronic myeloid leukemia presenting with extreme thrombocytosis simulating essential thrombocythemia","volume":"40","author":"Boklan","year":"2018","journal-title":"J Pediatr Hematol Oncol."},{"issue":"6","key":"2023110721223212100_CIT0005","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/bjh.16599","article-title":"TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries","volume":"190","author":"Turkina","year":"2020","journal-title":"Br J Haematol."},{"issue":"13","key":"2023110721223212100_CIT0006","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1002\/cam4.3004","article-title":"MERGE: a multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey and Algeria","volume":"9","author":"Yassin","year":"2020","journal-title":"Cancer Med"},{"issue":"20","key":"2023110721223212100_CIT0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"7","key":"2023110721223212100_CIT0008","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(07)70206-1","article-title":"JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia","volume":"8","author":"Kramer","year":"2007","journal-title":"Lancet Oncol."},{"issue":"11","key":"2023110721223212100_CIT0009","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1016\/j.leukres.2009.06.011","article-title":"JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia","volume":"33","author":"Campiotti","year":"2009","journal-title":"Leuk Res."},{"issue":"3","key":"2023110721223212100_CIT0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/ijlh.12798","article-title":"Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"40","author":"Lewandowski","year":"2018","journal-title":"Int J Lab Hematol."},{"issue":"1","key":"2023110721223212100_CIT0011","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3892\/ol.2016.4631","article-title":"Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up","volume":"12","author":"Pagnano","year":"2016","journal-title":"Oncol Lett"},{"issue":"1","key":"2023110721223212100_CIT0012","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0300-1652.149177","article-title":"Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm","volume":"56","author":"Hassan","year":"2015","journal-title":"Niger Med J"},{"issue":"9","key":"2023110721223212100_CIT0013","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2006-12-061135","article-title":"Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation","volume":"109","author":"Hussein","year":"2007","journal-title":"Blood."},{"issue":"1","key":"2023110721223212100_CIT0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12185-013-1480-z","article-title":"Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation","volume":"99","author":"Xu","year":"2014","journal-title":"Int J Hematol."},{"issue":"11","key":"2023110721223212100_CIT0015","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.5858\/2007-131-1719-TOPVTC","article-title":"Transformation of polycythemia vera to chronic myelogenous leukemia","volume":"131","author":"Mirza","year":"2007","journal-title":"Arch Pathol Lab Med."},{"issue":"5","key":"2023110721223212100_CIT0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404591","article-title":"Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia","volume":"21","author":"Inami","year":"2007","journal-title":"Leukemia."},{"issue":"8","key":"2023110721223212100_CIT0017","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","article-title":"Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis","volume":"21","author":"Bornhauser","year":"2007","journal-title":"Leukemia."},{"issue":"7","key":"2023110721223212100_CIT0018","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","article-title":"JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders","volume":"22","author":"Cambier","year":"2008","journal-title":"Leukemia."},{"issue":"8","key":"2023110721223212100_CIT0019","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood."},{"issue":"3","key":"2023110721223212100_CIT0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3343\/alm.2013.33.3.229","article-title":"Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR\/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment","volume":"33","author":"Park","year":"2013","journal-title":"Ann Lab Med"},{"issue":"2","key":"2023110721223212100_CIT0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-008-0131-2","article-title":"Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia","volume":"88","author":"De Conchon","year":"2008","journal-title":"Int J Hematol."},{"issue":"1","key":"2023110721223212100_CIT0022","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0609.2008.01063.x","article-title":"A case of coexistence between JAK2V617F and BCR\/ABL","volume":"81","author":"Pardini","year":"2008","journal-title":"Eur J Haematol."},{"issue":"6","key":"2023110721223212100_CIT0023","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.leukres.2007.10.018","article-title":"Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders","volume":"32","author":"Kim","year":"2008","journal-title":"Leuk Res."},{"issue":"5","key":"2023110721223212100_CIT0024","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","article-title":"Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation","volume":"22","author":"Hussein","year":"2008","journal-title":"Leukemia."},{"issue":"4","key":"2023110721223212100_CIT0025","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1016\/j.leukres.2009.09.025","article-title":"A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm","volume":"34","author":"Veronese","year":"2010","journal-title":"Leuk Res."},{"issue":"1","key":"2023110721223212100_CIT0026","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.leukres.2009.08.009","article-title":"Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR-ABL oncoprotein and JAK2V617F mutation","volume":"34","author":"Caocci","year":"2010","journal-title":"Leuk Res."},{"issue":"1","key":"2023110721223212100_CIT0027","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/2162-3619-2-24","article-title":"Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F","volume":"2","author":"Pastore","year":"2013","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2023110721223212100_CIT0028","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s12185-013-1326-8","article-title":"Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate","volume":"97","author":"Lee","year":"2013","journal-title":"Int J Hematol."},{"key":"2023110721223212100_CIT0029","first-page":"738428","article-title":"Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenous leukemia, and a Jak 2 positive myeloproliferative disorder","volume":"2014","author":"Maerki","year":"2014","journal-title":"Case Rep Hematol"},{"issue":"9","key":"2023110721223212100_CIT0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.12998\/wjcc.v7.i9.1087","article-title":"Coexistence of breakpoint cluster region-Abelson 1 rearrangement and janus kinase 2 V617F mutation in chronic myeloid leukemia: a case report","volume":"7","author":"Shi","year":"2019","journal-title":"World J Clin Cases"},{"issue":"5","key":"2023110721223212100_CIT0031","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ajh.21296","article-title":"BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome\/ myeloproliferative neoplasm (RARS-T)","volume":"84","author":"Gattenlohner","year":"2009","journal-title":"Am J Hematol."},{"issue":"2","key":"2023110721223212100_CIT0032","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.52.145","article-title":"Disappearance of both the BCR\/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia","volume":"52","author":"Inokuchi","year":"2012","journal-title":"J Clin Exp Hematol."},{"issue":"1","key":"2023110721223212100_CIT0033","first-page":"34","article-title":"The concomitant occurrence of JAK2V617F mutation and BCR\/ABL transcript with phenotypic expression- an overlapping myeloproliferative disorder or two distinct diseases? Case report","volume":"6","author":"Ursuleac","year":"2013","journal-title":"J Med Life"},{"issue":"5","key":"2023110721223212100_CIT0034","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","article-title":"Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation","volume":"9","author":"Pingali","year":"2009","journal-title":"Clin Lymphoma Myeloma."},{"key":"2023110721223212100_CIT0035","doi-asserted-by":"crossref","first-page":"e938488","DOI":"10.12659\/AJCR.938488","article-title":"A 68-year-old man with a cytogenetic diagnosis of chronic myeloid leukemia and bone marrow findings of Philadelphia chromosome translocation between the long arm of chromosomes 9 and 22, leading to the BCR-ABL1 fusion gene and V617F mutation in the JAK2 gene","volume":"24","author":"Warsi","year":"2023","journal-title":"Am J Case Rep"},{"issue":"7","key":"2023110721223212100_CIT0036","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1177\/1078155221991646","article-title":"Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: is there a correlation","volume":"27","author":"Frikha","year":"2021","journal-title":"J Oncol Pharm Pract."},{"issue":"1","key":"2023110721223212100_CIT0037","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1159\/000514632","article-title":"A case report of BCR-ABL-JAK2-positive chronic myeloid leukemia with complete hematological and major molecular response to dasatinib","volume":"14","author":"Ali","year":"2021","journal-title":"Case Rep Oncol"},{"issue":"9","key":"2023110721223212100_CIT0038","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2006.08.6884","article-title":"Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia","volume":"25","author":"Teofili","year":"2007","journal-title":"J Clin Oncol."},{"issue":"6","key":"2023110721223212100_CIT0039","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev."},{"issue":"3","key":"2023110721223212100_CIT0040","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14740\/jh822","article-title":"Essential thrombocythemia in children: a retrospective study","volume":"10","author":"Ameen","year":"2021","journal-title":"J Hematol"},{"issue":"1","key":"2023110721223212100_CIT0041","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jca.21847","article-title":"Therapeutic thrombocytapheresis in myeloproliferative neoplasms: a single-institution experience","volume":"36","author":"Nguyen","year":"2021","journal-title":"J Clin Apher."},{"key":"2023110721223212100_CIT0042","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2017.03.008","article-title":"The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review","volume":"58","author":"Boddu","year":"2017","journal-title":"Leuk Res."},{"issue":"1","key":"2023110721223212100_CIT0043","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2141.2002.03241.x","article-title":"Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide","volume":"116","author":"Voskaridou","year":"2002","journal-title":"Br J Haematol."},{"issue":"1","key":"2023110721223212100_CIT0044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.leu.2403556","article-title":"Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic leukemia","volume":"19","author":"Silver","year":"2005","journal-title":"Leukemia."},{"issue":"5","key":"2023110721223212100_CIT0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.leukres.2004.10.002","article-title":"Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders","volume":"29","author":"Fruchtman","year":"2005","journal-title":"Leuk Res."},{"issue":"26","key":"2023110721223212100_CIT0046","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomised CML study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood."},{"issue":"18","key":"2023110721223212100_CIT0047","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/cncr.30767","article-title":"Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents","volume":"123","author":"Millot","year":"2017","journal-title":"Cancer."},{"issue":"7","key":"2023110721223212100_CIT0048","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumors: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"issue":"1","key":"2023110721223212100_CIT0049","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr Blood Cancer."},{"issue":"1","key":"2023110721223212100_CIT0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.15264\/cpho.2021.28.2.93","article-title":"A pediatric case of atypical chronic myeloid leukemia with CSF3R mutation not responding to ruxolitinib, but rescued by allogeneic transplantation","volume":"28","author":"Choi","year":"2021","journal-title":"Clin Pediatr Hematol Oncol."},{"issue":"9","key":"2023110721223212100_CIT0051","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia."}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/6\/e170\/52799298\/lmad053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/54\/6\/e170\/52799298\/lmad053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T21:23:09Z","timestamp":1699392189000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/54\/6\/e170\/7205929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,23]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,23]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmad053","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,23]]}}}